HDAC and MEK inhibition synergistically suppresses HOXC6 and enhances PD-1 blockade efficacy in BRAFV600E-mutant microsatellite stable colorectal cancer

HDAC and MEK inhibition synergistically suppresses HOXC6 and enhances PD-1 blockade efficacy in BRAFV600E-mutant microsatellite stable colorectal cancer

Background B-Raf proto-oncogene, serine/threonine kinase (BRAF)V600E-mutant microsatellite stable (MSS) colorectal cancer (CRC) constitutes a distinct CRC subgroup, traditionally perceived as minimally responsive to standard therapies. Recent clinical attempts, such as BRAF inhibitors (BRAFi) monoth...

Full description

Saved in:

Bibliographic Details
Main Authors:	Xin Li, Peng Yang, Jin Gu, Nan Chen, Dengbo Ji, Jinhong Xia, Jinying Jia, Zhuang Sun, Mengyuan Shi, Hanyang Wang, Zhaoya Gao
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2025-01-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/13/1/e010460.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Management of asynchronous multifocal adult glioblastoma with loss of BRAFV600E -mutant clonality: a case report
by: Hannah Haile, et al.
Published: (2025-01-01)

Beyond BRAFV600E: Investigating the Clinical and Genetic Spectrum of Langerhans Cell Histiocytosis in Children
by: Xue Tang, et al.
Published: (2024-12-01)

A Micro-RNA Connection in BRafV600E-Mediated Premature Senescence of Human Melanocytes
by: Gang Ren, et al.
Published: (2012-01-01)

Mutational Analysis of BRAFV600E by Polymerase Chain Reaction in Breast Cancer: A Narrative Review
by: Simran Khan, et al.
Published: (2025-01-01)

Targeted Therapies Compared to Dacarbazine for Treatment of BRAFV600E Metastatic Melanoma: A Cost-Effectiveness Analysis
by: Vanessa Shih, et al.
Published: (2015-01-01)

BRAF inhibitor monotherapy in BRAFV600E-mutated pediatric low-grade glioma: a single center’s experience
by: S. S. McThenia, et al.
Published: (2025-01-01)

Evaluating the droplet digital PCR and direct Sanger sequencing for the detection of the BRAFV600E mutation in papillary thyroid carcinoma
by: Akankshya Dash, et al.
Published: (2024-09-01)

Loss of Lkb1 cooperates with BrafV600E and ultraviolet radiation, increasing melanoma multiplicity and neural‐like dedifferentiation
by: Kimberley McGrail, et al.
Published: (2025-02-01)

Targeting KRAS‐mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2
by: Satoru Miyazaki, et al.
Published: (2025-02-01)

Inter- and Intra-observer Reproducibility of Thyroid Fine Needle Aspiration Cytology: An investigation of Bethesda 2023 Using Immunohistochemical BRAFV600E Antibody
by: Erdogan Bahattin, et al.
Published: (2024-12-01)

Elucidating the Prognostic Role of BRAFV600E and the Activation Status of the Downstream MAPK Pathway in PTC: A Study from a Tertiary Centre in India
by: Nadeem Kocheri, et al.
Published: (2024-12-01)

Novel therapy: Combined BRAF and MEK inhibitors for locally advanced BRAF V600L–Positive mucosal melanoma in hypopharynx
by: Sivakamavalli Jeyachandran
Published: (2024-06-01)

BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report
by: Yasar Subutay Peker, et al.
Published: (2018-01-01)

The diagnostic and prognostic significance of HOXC13-AS and its molecular regulatory mechanism in human cancer
by: Xiaosi Gu, et al.
Published: (2025-02-01)

Escherichia coli combination with PD-1 blockade synergistically enhances immunotherapy in glioblastoma multiforme by regulating the immune cells
by: Guochen Li, et al.
Published: (2025-02-01)

A Case Presentation of a Patient with Microsatellite Instability and BRAF Mutant Metastatic Colon Cancer and Bibliography Update
by: K. Thomopoulou, et al.
Published: (2019-01-01)

Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy
by: Xia Liu, et al.
Published: (2022-10-01)

Sex and outcomes of patients with microsatellite instability-high and BRAF V600E mutated metastatic colorectal cancer receiving immune checkpoint inhibitors
by: Michael Hoffmeister, et al.
Published: (2025-02-01)

Synergistic strategies for glioblastoma treatment: CRISPR-based multigene editing combined with immune checkpoint blockade
by: Xiaolin Liu, et al.
Published: (2025-02-01)

Genomic microsatellite characterization and development of polymorphic microsatellites in Eospalax baileyi
by: Qiqi Hou, et al.
Published: (2025-01-01)

Tokay gecko tail regeneration involves temporally collinear expression of HOXC genes and early expression of satellite cell markers
by: Luthfi Nurhidayat, et al.
Published: (2025-01-01)

Exosomal circ_0006896 promotes AML progression via interaction with HDAC1 and restriction of antitumor immunity
by: Can Can, et al.
Published: (2025-01-01)

HDAC1 and HDAC2 Are Involved in Influenza A Virus-Induced Nuclear Translocation of Ectopically Expressed STAT3-GFP
by: Jessica Leong, et al.
Published: (2024-12-01)

HDAC10 and its implications in Sézary syndrome pathogenesis
by: Monika Pieniawska, et al.
Published: (2025-01-01)

A novel human specific lncRNA MEK6-AS1 regulates adipogenesis and fatty acid biosynthesis by stabilizing MEK6 mRNA
by: Di Li, et al.
Published: (2025-01-01)

Fitness landscapes of human microsatellites.
by: Ryan J Haasl, et al.
Published: (2024-12-01)

Inhibition of MEK1 Signaling Pathway in the Liver Ameliorates Insulin Resistance
by: Atsunori Ueyama, et al.
Published: (2016-01-01)

Targeted intervention of tumor microenvironment with HDAC inhibitors and their combination therapy strategies
by: Wanli Zhang, et al.
Published: (2025-02-01)

Human papillomavirus type 16 E7 promotes cell viability and migration in cervical cancer by regulating the miR-23a/HOXC8 axis
by: Yahang Chen, et al.
Published: (2024-12-01)

Medullary colonic carcinoma with microsatellite instability has lower survival compared with conventional colonic adenocarcinoma with microsatellite instability
by: Miguel A. Gómez-Álvarez, et al.
Published: (2016-12-01)

PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV
by: Diwakar Davar, et al.
Published: (2015-01-01)

MEK1/2 Inhibitor (GDC0623) Promotes Osteogenic Differentiation of Primary Osteoblasts Inhibited by IL-1β through the MEK-Erk1/2 and Jak/Stat3 Pathways
by: Zeng-Qiao Zhang, et al.
Published: (2021-01-01)

HDAC Inhibition Modulates Cardiac PPARs and Fatty Acid Metabolism in Diabetic Cardiomyopathy
by: Ting-I Lee, et al.
Published: (2016-01-01)

Discovery of novel biphenyl compounds bearing hydroxamic acid moiety as the first PD-L1/class I HDACs dual inhibitors
by: Dandan Yuan, et al.
Published: (2025-12-01)

GRHL3 Promotes Tumor Growth and Metastasis via the MEK Pathway in Colorectal Cancer
by: Lin Tan, et al.
Published: (2021-01-01)

Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy
by: Rangarirai Makuku, et al.
Published: (2021-01-01)

Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial
by: David Malka, et al.
Published: (2022-11-01)

HDAC6 Facilitates PRV and VSV Infection by Inhibiting Type I Interferon Production
by: Hu Zheng, et al.
Published: (2025-01-01)

Chidamide Suppresses the Growth of Cholangiocarcinoma by Inhibiting HDAC3 and Promoting FOXO1 Acetylation
by: Yongpan Li, et al.
Published: (2022-01-01)

Hypoxia-induced conversion of sensory Schwann cells into repair cells is regulated by HDAC8
by: Nadège Hertzog, et al.
Published: (2025-01-01)